Clinical Trial Update: Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation [Phase 1]

View source ↗

Summary

Phase 1 study of AG-120 (ivosidenib) for IDH1-mutant advanced solid tumors, including glioma, has completed enrollment and data collection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Chondrosarcoma
• Glioma

Drugs mentioned

• AG-120 (ivosidenib)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Cholangiocarcinoma, Chondrosarcoma | Phase 1 | Status: COMPLETED